RxDoctor Payments Data

Hailey Davis

Family · New Albany, MSNPI 1104327667

Payments from drug & device makers

$5,389in general payments, 2019–2025

Across 393 payments — averaging $13.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$439
  • GSK$433
  • Pfizer$312
  • Lilly USA, LLC$282
  • Abbott$206
  • plus $2K from 34 others

What the payments were for

  • Food & beverage$5,389100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,389 in reported general payments places this provider in the 90th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$63,114
Medicare patients
277
Services billed
1,676

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide106$124,767
FarxigaDapagliflozin Propanediol41$36,708
JardianceEmpagliflozin57$34,909
QuliptaAtogepant14$25,342
MounjaroTirzepatide23$24,116
EliquisApixaban27$19,848
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$19,620
VraylarCariprazine Hcl11$15,112
KerendiaFinerenone20$12,084
LinzessLinaclotide17$10,173
TradjentaLinagliptin15$5,914
Chlorpromazine Hcl12$5,244
DapagliflozinDapagliflozin Propanediol14$5,016
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog29$4,344
Telmisartan-AmlodipineTelmisartan/Amlodipine17$2,809

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$439$124,767106 claims
AbbVieQulipta, Vraylar, Linzess$1,233$50,62742 claims
Boehringer IngelheimJardiance, Tradjenta$200$40,82372 claims
AstraZenecaFarxiga$162$36,70841 claims
Lilly USA, LLCMounjaro$282$24,11623 claims
PfizerEliquis$312$19,84827 claims
GSKTrelegy Ellipta$433$19,62033 claims
BayerKerendia$170$12,08420 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,007 family providers in Mississippi.

Other family in New Albany

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →